Compare Stocks → SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ADMPNASDAQ:BLPHNASDAQ:BPTHNASDAQ:CLSNNASDAQ:JAGX Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADMPAdamis Pharmaceuticals$1.28$0.75▼$26.18$7.26M1.27811,695 shs119,800 shsBLPHBellerophon Therapeutics$0.05$0.05$0.03▼$11.15$625K0.6762,212 shs2,320 shsBPTHBio-Path$2.92-31.9%$5.28$2.70▼$44.80$1.99M0.361.16 million shs863,854 shsCLSNImunon$2.22$1.80▼$15.75$13.91M2.27150,471 shs711 shsJAGXJaguar Health$0.18+12.5%$0.09$0.05▼$1.22$49.69M1.3551.39 million shs105.42 million shsInvesting Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADMPAdamis Pharmaceuticals0.00%0.00%0.00%0.00%-88.22%BLPHBellerophon Therapeutics-6.07%-10.43%-7.09%-15.47%-99.49%BPTHBio-Path-31.93%-1.02%-32.95%-64.48%-89.57%CLSNImunon0.00%0.00%0.00%0.00%0.00%JAGXJaguar Health+14.66%+51.43%+150.21%+81.17%-68.43%SHOCKING Crypto Leak… (Ad)A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. Claim your free seat by clicking here now.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADMPAdamis PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ABLPHBellerophon Therapeutics2.0962 of 5 stars3.00.00.04.83.20.00.6BPTHBio-Path1.3445 of 5 stars3.52.00.00.02.30.00.6CLSNImunonN/AN/AN/AN/AN/AN/AN/AN/AJAGXJaguar HealthN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADMPAdamis PharmaceuticalsN/AN/AN/AN/ABLPHBellerophon Therapeutics2.00Hold$2.003,813.89% UpsideBPTHBio-Path3.00Buy$40.001,269.86% UpsideCLSNImunonN/AN/AN/AN/AJAGXJaguar HealthN/AN/AN/AN/ACurrent Analyst RatingsLatest BLPH, ADMP, JAGX, CLSN, and BPTH Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/18/2024BPTHBio-PathRoth MkmSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$40.003/27/2024BPTHBio-PathRoth MkmSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$12.00 ➝ $40.00(Data available from 4/23/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADMPAdamis Pharmaceuticals$4.76M0.00N/AN/A($1.26) per share0.00BLPHBellerophon TherapeuticsN/AN/AN/AN/A$0.27 per shareN/ABPTHBio-PathN/AN/AN/AN/A$0.71 per shareN/ACLSNImunon$500K0.00N/AN/A$9.66 per share0.00JAGXJaguar Health$9.76M5.09N/AN/A$0.07 per share2.57Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADMPAdamis Pharmaceuticals-$26.48MN/A0.00N/AN/A-502.73%-420.53%-256.87%N/ABLPHBellerophon Therapeutics-$19.83M-$0.84N/A∞N/AN/A-187.35%-104.97%5/13/2024 (Estimated)BPTHBio-Path-$16.08M-$40.80N/AN/AN/AN/A-375.74%-248.63%5/10/2024 (Estimated)CLSNImunon-$20.77MN/A0.00N/AN/A-5,229.80%-50.18%-36.94%N/AJAGXJaguar Health-$41.30MN/A0.00∞N/A-423.11%-837.11%-80.76%5/20/2024 (Estimated)Latest BLPH, ADMP, JAGX, CLSN, and BPTH EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/8/202412/31/2023BPTHBio-Path-$5.40-$5.40N/AN/AN/AN/A DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADMPAdamis PharmaceuticalsN/AN/AN/AN/AN/ABLPHBellerophon TherapeuticsN/AN/AN/AN/AN/ABPTHBio-PathN/AN/AN/AN/AN/ACLSNImunonN/AN/AN/AN/AN/AJAGXJaguar HealthN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADMPAdamis PharmaceuticalsN/A0.230.19BLPHBellerophon TherapeuticsN/A3.963.96BPTHBio-PathN/A1.601.60CLSNImunon0.136.526.52JAGXJaguar Health6.332.001.34OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADMPAdamis Pharmaceuticals38.55%BLPHBellerophon Therapeutics10.61%BPTHBio-Path5.74%CLSNImunon12.97%JAGXJaguar Health12.04%Insider OwnershipCompanyInsider OwnershipADMPAdamis Pharmaceuticals1.30%BLPHBellerophon Therapeutics5.20%BPTHBio-Path3.05%CLSNImunon4.66%JAGXJaguar Health0.02%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableADMPAdamis Pharmaceuticals119.36 million9.24 millionOptionableBLPHBellerophon Therapeutics1812.23 million11.60 millionNo DataBPTHBio-Path10680,000658,000OptionableCLSNImunon277.10 million6.77 millionOptionableJAGXJaguar Health49276.22 million276.16 millionNo DataBLPH, ADMP, JAGX, CLSN, and BPTH HeadlinesSourceHeadlineNapo Pharmaceuticals, a Jaguar Health Family Company, to Exhibit at Oncology Nursing Society (ONS) Congress in Support of Company's Expanding Focus on Cancer Supportive Careaccesswire.com - April 22 at 8:45 AMJaguar Health (NASDAQ:JAGX) Now Covered by StockNews.comamericanbankingnews.com - April 22 at 2:16 AMJaguar Health gets grant for treating secretory diarrhea associated with microvillous inclusion diseasepharmaceutical-technology.com - April 18 at 11:23 AMJaguar Health Appoints Biopharmaceutical Industry…pharmiweb.com - April 18 at 11:23 AMJaguar Health Appoints Biopharmaceutical Industry Veteran to Execute Company's In-licensing Growth Strategy in the Areas of Cancer and GI Supportive Careaccesswire.com - April 18 at 8:30 AMJaguar Health licenses Venture Life's US FDA-approved oral mucositis product, Gelclair for US marketpharmabiz.com - April 18 at 6:22 AMWhy Jaguar Health Stock Is Up Todaymsn.com - April 17 at 2:20 AMGold Moves Higher; Morgan Stanley Earnings Top Viewsmarkets.businessinsider.com - April 17 at 2:20 AMWhy Is Jaguar Health (JAGX) Stock Up 44% Today?investorplace.com - April 16 at 11:34 AMJaguar Health Licenses FDA-Approved Oral Mucositis Product for U.S. Market, Initiating Commercial Footprint in its Core Focus Area of Cancer Supportive Careaccesswire.com - April 16 at 8:30 AMJaguar Health (NASDAQ:JAGX) Receives New Coverage from Analysts at StockNews.comamericanbankingnews.com - April 14 at 2:16 AMS&P 500 Down 1%; Delta Air Lines Posts Upbeat Earningsbenzinga.com - April 10 at 3:37 PMJaguar Health shareholders approve reverse stock splitmsn.com - April 10 at 3:37 PMWhat Is Going on With Jaguar Health (JAGX) Stock Today?investorplace.com - April 10 at 10:40 AMJaguar Health, Inc.: Jaguar Health Reports Approval of All Proposals at April 2024 Special Meeting of Stockholdersfinanznachrichten.de - April 10 at 1:23 AMWhy Jaguar Health Stock Is Soaring After-Hoursmsn.com - April 9 at 8:04 PMJaguar Health Reports Approval of All Proposals at April 2024 Special Meeting of Stockholdersaccesswire.com - April 9 at 4:15 PMJaguar Health Granted Extension Until August 13, 2…pharmiweb.com - April 8 at 9:51 AMJaguar Health Granted Extension Until August 13, 2024, to Regain Compliance with Nasdaq's Bid Price Requirementaccesswire.com - April 8 at 8:30 AMJaguar Health Full Year 2023 Earnings: US$1.79 loss per share (vs US$36.18 loss in FY 2022)finance.yahoo.com - April 3 at 9:48 AMJaguar Health, Inc. (NASDAQ:JAGX) Q4 2023 Earnings Call Transcriptfinance.yahoo.com - April 2 at 1:47 PMJaguar Health Appoints European Pharmaceutical Industry Leader as President of Jaguar Internationalaccesswire.com - April 2 at 8:50 AMJAGX Stock Earnings: Jaguar Health Misses Revenue for Q4 2023investorplace.com - April 1 at 2:08 PMJaguar Health, Inc.: Jaguar Health Reports 2023 Financial Resultsfinanznachrichten.de - April 1 at 10:51 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAdamis PharmaceuticalsNASDAQ:ADMPAdamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy, opioid overdose, respiratory, and inflammatory disease. Its products include SYMJEPI epinephrine injection for the emergency treatment of allergic reactions to stinging and biting insects, allergen immunotherapy, foods, drugs, diagnostic testing substances, and other allergens, as well as idiopathic or exercise-induced anaphylaxis; and ZIMHI naloxone injection for the treatment of opioid overdose. The company is headquartered in San Diego, California.Bellerophon TherapeuticsNASDAQ:BLPHBellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its primary product is INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension. The company engages in the development of INOpulse, which is in Phase 3 clinical trial for the treatment of pulmonary hypertension associated with fibrotic interstitial lung disease; which has completed Phase 2a clinical trial for pulmonary hypertension associated with chronic obstructive pulmonary disease; and that has completed Phase 2 dose escalation stage for pulmonary hypertension associated with sarcoidosis, as well as for chronic thromboembolic pulmonary hypertension and pulmonary hypertension associated with pulmonary edema from high altitude sickness. The company was formerly known as Ikaria Development LLC and changed its name to Bellerophon Therapeutics, Inc. in January 2014. Bellerophon Therapeutics, Inc. was founded in 2009 and is headquartered in Warren, New Jersey.Bio-PathNASDAQ:BPTHBio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. It is also developing Liposomal Bcl-2 (BP1002) for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; Liposomal STAT3 (BP1003) for the treatment of pancreatic cancer, non-small cell lung cancer, and AML; and BP1001-A for the treatment of solid tumors. Bio-Path Holdings, Inc. was founded in 2007 and is based in Bellaire, Texas.ImunonNASDAQ:CLSNCelsion Corporation, a clinical stage biotechnology company, focuses on the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. Its product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer; and ThermoDox, a proprietary heat-activated liposomal encapsulation of doxorubicin, which is in development stage for various cancer indications. The company also has two feasibility stage platform technologies for the development of nucleic acid-based immunotherapies, vaccines, and other anti-cancer DNA or RNA therapies. Celsion Corporation was founded in 1982 and is based in Lawrenceville, New Jersey.Jaguar HealthNASDAQ:JAGXJaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It markets Mytesi for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The company also develops Crofelemer, which is in Phase 3 clinical trial for or prophylaxis of diarrhea in adult cancer patients, and to address rare/orphan disease indications, including Short bowel syndrome with intestinal failure and/or congenital diarrheal disorders; supportive care for diarrhea relief in inflammatory bowel diseases; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, it develops NP-300, a second-generation proprietary anti-secretory antidiarrheal drug for symptomatic relief and treatment of moderate-to-severe diarrhea; and Canalevia, an oral plant-based drug candidate to treat chemotherapy-induced diarrhea in dogs and exercise-induced diarrhea in dogs. The company was founded in 2013 and is headquartered in San Francisco, California. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.